Top Injectable Testosterone Brands: A Quick Guide

When it comes to injectable testosterone, ensuring quality and efficacy is paramount. Many healthcare providers rely on reputable brands to deliver consistent and safe results. Some of the top brands known for their reliability in the field of testosterone delivery include Pfizer with its highly regarded Depo-Testosterone, Sandoz with their cost-effective alternatives, and Teva Pharmaceuticals, known for their rigorous quality controls. For those looking to optimize hormone therapy, we’ve compiled a list of the best brands for injectable testosterone just below.

Illustration of injectable testosterone

Best brands of injectable testosterone in 2025

Pfizer

Pfizer Inc. is a leading producer of injectable testosterone, contributing significantly to the global testosterone replacement therapy market. The company's products, such as testosterone cypionate, are highly effective and widely adopted by medical professionals, with the testosterone cypionate segment dominating the market share in 2022. The global testosterone replacement therapy market, which includes Pfizer's offerings, is projected to grow from USD 1.98 Billion in 2023 to USD 2.93 Billion by 2033 at a CAGR of 4.0%. Pfizer's presence in this market is bolstered by its strong healthcare infrastructure and significant target patient base, particularly in North America, where the company holds a substantial market share. The increasing awareness of testosterone deficiency and its health benefits further drives the demand for Pfizer's injectable testosterone products.

Bayer

Bayer AG is a leading producer of injectable testosterone, contributing significantly to the global market that is expected to grow at a CAGR of around 4% from 2023 to 2036. The company's products are widely used to treat hypogonadism, a condition that affects a substantial portion of the male population, particularly those aged 40 to 79. With the global testosterone injectable market valued at USD 2.08 billion in 2023 and projected to exceed USD 3.42 billion by 2036, Bayer's offerings are crucial in addressing the increasing prevalence of testosterone deficiency. The high healthcare expenditure, especially in the United States, where spending on healthcare increased by 9.7% in 2020 to USD 4.1 trillion, further supports the growth of Bayer's injectable testosterone products. Bayer's commitment to quality and efficacy makes it a trusted brand in the hormone replacement therapy market.

Cipla

Cipla, a renowned global pharmaceutical company, is a leading producer of injectable testosterone cypionate, known for its commitment to making medicines accessible and affordable. Established in 1935, Cipla has a strong presence in over 85 markets, including India, South Africa, and North America. The company is the third largest pharmaceutical corporation in India and South Africa's private market, with a significant growth rate, such as a 4.8% growth in the South African private market in FY 2022-23. Cipla's product portfolio includes complex generics and a wide range of therapeutic segments, and it has been a pioneer in introducing essential drugs, including anti-retroviral therapies. With 47 manufacturing sites worldwide, Cipla ensures high-quality production of its testosterone cypionate injections.

Watson Pharmaceuticals

Watson Pharmaceuticals, now part of Teva Pharmaceutical Industries, has been a significant player in the testosterone replacement therapy (TRT) market, particularly with its brand product Androderm, a transdermal testosterone patch. In 1999, Watson reacquired the marketing rights to Androderm, which is part of their General Products line. The company has a strong presence in the U.S. generics market, with over 150 generic products, and its Brand division focuses on urology and nephrology, including testosterone replacement therapies. Watson's Androderm has been a key product in the TRT market, competing with other major brands like AndroGel and Axiron. The company's commitment to quality, integrity, and customer service has solidified its position as a reliable provider of pharmaceutical products.

Teva Pharmaceuticals

Teva Pharmaceuticals is a prominent player in the testosterone replacement therapy market, particularly in the injectable segment, which accounted for the highest market share of 31.01% in 2022. As a global leader, Teva offers a wide range of pharmaceutical products, including generics, branded drugs, and active pharmaceutical ingredients. The company's extensive manufacturing capabilities, with over 53 facilities in more than 33 countries, enable it to produce approximately 76 billion tablets and capsules annually. Teva's commitment to innovation and quality has made it a significant contributor to the healthcare industry, serving about 200 million people daily. Its global presence and diverse product portfolio solidify its position as a major producer of injectable testosterone.

Endo Pharmaceuticals

Endo Pharmaceuticals is a leading producer of injectable testosterone, known for its high-quality and life-enhancing therapies. The company partners with hospitals and healthcare systems to provide sterile injectable products, including testosterone replacements, which are prescribed by endocrinologists, urologists, and general practitioners. In the testosterone replacement therapy market, Endo Pharmaceuticals is one of the dominant players, along with other major companies like AbbVie Inc and Pfizer Inc. The hospital segment, where Endo's products are widely used, is expected to hold a significant revenue share of around 45% by 2036. Endo's commitment to innovation and patient care is evident in its century-long manufacturing legacy and its recent product launches, such as NATESTO, the first and only nasal gel for testosterone replacement therapy.

Sun Pharmaceuticals

Sun Pharmaceutical Industries Limited, one of the world's leading generic pharmaceutical companies, is a prominent producer of injectable testosterone products, including testosterone cypionate. With global revenues of US$ 5.4 billion and a strong presence in over 100 countries, Sun Pharma invests up to 6-8% of its revenues in Research and Development annually. The company's extensive portfolio includes technologically complex products like injectables, which are crucial in the testosterone replacement therapy market. Sun Pharma's commitment to innovation and quality has made it a key player in the global testosterone cypionate injection market, alongside other major companies like Pfizer and Perrigo. Its dedicated teams in formulations, process chemistry, and analytical development ensure high-quality products. You can learn more about their innovations and offerings on the Sun Pharma website.

Watson/Actavis

Watson/Actavis, now part of Allergan, is a prominent player in the testosterone replacement therapy (TRT) market, particularly with its Androderm® testosterone transdermal system. In 2011, the FDA approved the new 2 mg and 4 mg formulations of Androderm®, which provided a 20 percent reduction in the active ingredient and a smaller patch size, enhancing patient convenience and efficacy. This product has been successfully marketed in the U.S. and has contributed to the company's strong presence in the TRT market, with Actavis holding a 5 percent share of the testosterone replacement market in 2012. The company's strategic product launches and marketing efforts have been instrumental in its market position. Actavis's global commercial strength and extensive R&D network further solidify its reputation as a leading producer of TRT products.

Hikma Pharmaceuticals

Hikma Pharmaceuticals is a leading manufacturer of injectable medicines, including testosterone products, known for its high-quality and reliable offerings. As one of the largest manufacturers of sterile injectable medicines in the US, Hikma serves thousands of hospitals and millions of patients. The company has a significant presence in the global testosterone replacement therapy market, which is expected to grow at a CAGR of 4.50% from 2024 to 2031, with injectables being the dominant category due to their stability and effectiveness. Hikma's extensive portfolio and manufacturing capabilities, including over 31 manufacturing facilities and 7 R&D centers, position it as a trusted partner in the pharmaceutical industry. Hikma's commitment to quality and customer service further solidifies its reputation as a top producer of injectable testosterone products.

Sandoz

Sandoz, a renowned pharmaceutical company, is a significant player in the testosterone injectable market, known for its high-quality and efficient hormone replacement therapies. The global testosterone injectable market, which includes Sandoz's products, is projected to grow from USD 2.16 billion in 2024 to USD 3.55 billion by 2037, with a CAGR of 3.9% during the forecast period. Sandoz's contributions to this market are driven by increasing healthcare expenditure and improved healthcare infrastructure, with hospitals accounting for a 45% revenue share in the distribution and administration of testosterone injectables. The European market, where Sandoz has a strong presence, is expected to acquire a notable share due to the presence of various medical centers and rising government initiatives. The growing demand for testosterone replacement therapy, with a market expected to reach USD 2.9 billion by 2031, further underscores Sandoz's importance in this sector.